Leishmania
Genetic Engineering Produces Safe, Live Vaccine
Published in Gene Therapy Weekly, November 13th, 1995
Leishmaniasis is endemic in 86 countries, including the U.S., and affects some 12 million people. The disease spectrum ranges from localized cutaneous infections to a fatal visceral disease. Other than vaccine, there is no preventive agent against this infection. Current treatments are both toxic and expensive.
The good news is that once the body elicits an immune response against the disease, reinfection is not likely. This should mean that a vaccine could be developed relatively simply, however, there is currently no safe and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (1995-11-13)
More Articles from Gene Therapy Weekly
- Biological Hazards
Vector No Longer Restricts Itself to Insect Cells: Infects Humans, Too - Conference Coverage (ICAAC)
New Strategies Revolutionize Vaccinology - Conference Coverage (ICAAC)
The Wave of the Future: Nucleic Acid Vaccines - Alzheimer's Disease
Blood-Brain Barrier Bypassed, Diagnostic Potential Seen - Breast Cancer (Prognosis)
Understanding of the p53 Gene's Role in Cancer - Cancer Gene Therapy
In Vivo Experiments Compare Two Genetically Engineered Therapies - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
